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Mental state of demoralisation across diverse clinical settings: A systematic review, metaanalysis and proposal for its use as a ‘specifier’ in mental illness
Lucy L Gan1,2 , Susanna Gong3 and David W Kissane3,4,5
Abstract
Objective: Demoralisation is a state of poor coping characterised by low morale, hopelessness, subjective incompetence,
and loss of meaning and purpose in life. While studied extensively in oncology and palliative care, there has been
recent exploration in broader medical and mental health settings. The aim was to investigate the prevalence of demoralisation
and associated sociodemographic and psychological factors across these clinical settings.
Method: Six electronic databases were used to locate articles from January 2014 to March 2020. A pre-publication update of non-oncology populations
was completed in September 2021. The review has been reported following Preferred Reporting Items for Systematic Reviews and Meta-Analyses
guidelines. Pooled prevalence of demoralisation was
determined through % prevalence and mean demoralisation score; this was synthesised through meta-analysis of single means to determine pooled
mean prevalence of Demoralisation Scale scores using the ‘R’ statistical software.
Results: Demoralisation has been examined in 52 studies (n = 11,670) and found to be prevalent in 24–35% of oncology and non-oncology, including
mental health, populations. The mean score on the Demoralisation Scale was 24.3 (95%
confidence interval, CI = [21.3, 27.3]). There was evidence of divergent validity in addition to significant comorbidity between depression,
demoralisation and suicidal ideation. Burdensome physical symptoms, and psychological and demographic factors are strongly correlated with
demoralisation.
Conclusion: There remains a need to recognise demoralisation in various clinical and cultural settings and to strongly consider its inclusion as a ‘
specifier’ within formal nosological systems for adjustment and depressive disorders. This is important to initiate targeted interventions and prevent
significant morbidity.
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INTRODUCTION
Demoralisation is a state of poor coping characterised by low morale, hopelessness and loss of meaning and purpose in life (Kissane et al.,
2001). The origins of the construct arise from early observations of suffering and the contribution to coping of finding meaning, as expressed
by prominent psychiatrist Viktor Frankl (Frankl, 1962). The concept was furthered by Engel’s description of the ‘giving up - given up’ complex,
with hopeless cognitions worsening physical health (Engel, 1967). Around the same time, Jerome Frank conceptualised demoralisation as a
sense of internalised failure, which then contributes to perceived meaningless in life (Frank, 1974). Subjective incompetence deepens any
sense of helplessness and hopelessness (de Figueiredo and Frank, 1982). Demoralisation develops across a spectrum of severity from initial
feelings of disheartenment, to a deeper sense of hopelessness and failure, to a severe sense of loss of meaning and purpose (Kissane et al.,
2004).

This early literature led to the empirical assessment of demoralisation, with consideration of diagnostic parameters as well as implications for
targeted psychotherapeutic interventions, including meaning-based therapy (Robinson et al., 2016a). Validated measures were developed,
including the Diagnostic Criteria for Psychosomatic Research /Demoralisation (DCPR/D) (Fava et al., 1995) and the Demoralisation Scale (DS)
(Kissane et al., 2004). These two measures are the main primary validated measures of demoralisation utilised in previous literature (Robinson

et al., 2016a). The DCPR, first developed in 1995, is a set of diagnostic criteria based on an interview that aims to elicit various psychosomatic
syndromes in the medically ill across the clinical domains of stress, personality, illness behaviour and psychological sequelae- (Fava et al.,
2017). It has demonstrated utility in multiple studies and reviews (Sirri and Fava, 2013; Porcelli and Guidi, 2015) and has undergone further
revision in 2017 with fresh emphasis on the expression of hopelessness and helplessness in demoralisation syndrome. (Fava et al., 2017). The
DS is a 24-item self-report measure rated on a 3-point Likert scale, involving five subscales that assess various dimensions of demoralisation
including loss of life meaning, disheartenment, helplessness and sense of failure (Kissane et al., 2004). The DS underwent subsequent
refinement and revalidation to the DS-II, with re-evaluation as a 16 item scale with strong internal, convergent and divergent validity
(Robinson et al., 2016c). In comparing the DS and DS-II, the longer DS has a critical threshold score of >30, compared to >8 in the briefer DS-II
(Kissane et al., 2004; Robinson et al., 2016c). In comparing the DS with the DCPR/D, the DCPR/D utilises a longer time frame to evaluate
symptoms (1 month compared to 2 weeks in the DS), as well as reduced focus on phenomena such as loss of meaning or dysphoria that are
examined in the DS.

The neurobiology of demoralisation involves dopamine circuits, wherein motivational salience, desire and hope are activated in the shell
region of the nucleus accumbens, with the values placed on these goals considered in the orbital prefrontal cortex, memory consolidated in
the hippocampus, and then motor plans are encoded in the core region of the nucleus accumbens and dorsal striatum (Salgado and Kaplitt,

2015).These frontal-subcortical circuits play a key role in the hope system, with stress and trauma disrupting the dopamine system in the
nucleus accumbens (Leach, 2018).

Conceptually and from a phenomenological perspective, demoralisation has been most studied in oncology and palliative care settings, but
also with other medical and mental illnesses, among refugees, substance users, the postnatal period and in adjustment to stressors (Briggs,
2011; De Weert et al., 2017; Bobevski et al., 2014; Bobevski et al., 2015). This has contributed to a broader understanding of the prevalence of
demoralisation and the implications for treatment. One key focus has been the differentiation of demoralisation from depression, anxiety,
adjustment disorder and grief (Wellen, 2010; Figueiredo, 2013).

In 2015, three systematic reviews of demoralisation were undertaken in cancer (Tang et al., 2015), palliative care patients (Robinson et al.,
2015), and in diffuse clinical settings (Tecuta et al., 2015).Using the DS, a prevalence rate of 13-18% was found among palliative care patients
(Robinson et al., 2015). Using the DCPR/D, one third of the medically ill and one half of the mentally ill become demoralised (Tecuta et al.,
2015). Additionally, demoralisation and depression were seen to be independent and distinguishable (Tang et al., 2015; Tecuta et al., 2015).
Tecuta et al., 2015 identified associations between demoralisation and lower social support, increased stress, the presence of pain and
somatisation syndromes, illness behaviour and adverse health outcomes. Robinson et al., 2014 also identified a positive relationship between

demoralisation and physical symptoms, depression, anxiety, desire for hastened death and negative quality of life. Tang et al., 2015
emphasised the strong presence of depression in patients with high demoralisation and reported on the increased risk of suicide.
Our objective here was to update these prior reviews by examining recent studies of demoralisation across the past seven years (2014-2020) in
various clinical populations and settings. We aimed to synthesise evidence of the associations between demoralisation and various
sociodemographic and psychological factors. This systematic review aimed to answer the following key research questions:


What is the prevalence of demoralisation in studies from 2014 to 2020 inclusively?



What is the relationship between demoralisation and other related clinical syndromes?



What are the findings of recent psychometric analysis of demoralisation syndrome?



What sociodemographic, physical health and psychological factors influence the prevalence of demoralisation in these patient groups?



What impact does demoralisation have on quality of life and risk of suicide?



How might demoralisation be incorporated into the Diagnostic and Statistical Manual of Mental Disorders?

METHODS
Six electronic databases were used to locate articles: Medline, Embase, PsychINFO, Cumulative Index to Nursing & Allied Health Literature
(CINAHL), The Cochrane Library and PubMed. References of eligible papers were also manually searched for suitable articles for inclusion. The

search term (Demorali*) was used across all databases in screening titles, keywords and abstracts. PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analysis) methodology was used to guide this review (Liberati et al., 2009; Moher et al., 2009). Two reviewers
(LG and SG) independently assessed studies against the inclusion/exclusion criteria, and full texts for eligible articles were reviewed.

Selection criteria
We included peer-reviewed quantitative articles in which demoralisation prevalence was reported and validated measures of demoralisation
were used, including the DCPR and DS. Searches were limited to articles published in English between 1st of January 2014 to the 9th of March
2020 (when searches were completed). We excluded conference abstracts, dissertations/theses, studies involving non-clinical or non-medical
populations and studies where validated measures were not used. Studies where demoralisation prevalence was not reported or where
demoralisation was described primarily as a secondary outcome to validate a novel scale, measure or intervention were also excluded.
Additionally, data that were not complete or in process at the time of review were also excluded.

Data Extraction

The following data were extracted from the articles by the first author (LG): study design, sample characteristics including illness and sample
size, objective of study, measures used, prevalence results and other key findings. A separate reviewer (SG) reviewed and confirmed the
extracted data from the studies included in this review.

Data synthesis
The principal summary measure was pooled prevalence of demoralisation by way of overall mean demoralisation score and % prevalence.
Results were synthesised through meta-analysis of single means to determine pooled mean prevalence of Demoralisation Scale scores. The ‘R’
statistical software (R Development Core Team, 2010) and it’s ‘Metamean’ package was used to calculate pooled mean prevalence, 95% CI,
investigate heterogeneity (I squared and tau squared scores) and generate forest plots of overall pooled mean prevalence using Random
effects model. Sidik-Jonkman estimator was utilised to determine between study variance. Subgroup analysis was performed in oncology and
non-oncology studies, and further subgroup analysis was performed in advanced cancer populations.
In studies where demoralisation percentage prevalence was reported, including studies utilising the DCPR/D measure, % prevalence was
combined to determine mean % prevalence and range.

Quality appraisal and risk of bias

The quality of included articles was assessed using the Standard Quality Assessment Criteria for Evaluating Primary Research Papers from a
Variety of Fields (Kmet et al., 2004). This measure also considers risk of bias in individual studies and contributes to the overall quality score for
each article.

RESULTS
Through database searching, we initially identified 1513 articles. After screening for eligibility, we retained 40 articles that measured
prevalence of demoralisation, please see Figure 1 for PRISMA study selection flow.

This systematic review represents the experiences of 9,920 participants, including 7,093 oncology and 2,827 non-oncology participants. The
range of sample sizes across all included studies was 55 - 1,529 (mean = 248). There were 22 studies examining oncology populations, 17 nononcology medical populations, and one with mixed oncology and chronic illness participants. Of the non-oncology studies, 4 studies
investigated demoralisation in cardiovascular disease/cardiac surgery patients, 2 each for chronic illness, mothers in the postnatal period,
psychiatric conditions (one for eating disorders and one for patients with substance use disorders and psychiatric comorbidity), Parkinson’s
populations, and 1 each examined patients with psoriasis, fibromyalgia/rheumatoid arthritis, multiple sclerosis, tremor, primary care
populations and those on general medical wards.

In total, 34 studies utilised the Demoralisation Scale, 11 studies used the DCPR and 5 studies used both DS/DCPR study measures. Of the
included studies, 29 reported results involving mean + SD, the remaining reported demoralisation as a % prevalence.
There were 34 cross sectional studies, 5 longitudinal studies and 1 randomised control trial included in this review. Two studies (Li et al., 2016)
(Li et al., 2017) included in this review reported different relevant analysis findings based on the same study population.

The quality scores of articles ranged between a score of 0.75-1 (with 1 being the highest quality score) according to the Standard Quality
Assessment Criteria for Evaluating Primary Research Papers from a Variety of Fields (Kmet et al., 2004). The main source of bias was
recruitment bias through convenience sampling; smaller sample sizes were identified in studies with poorer quality scores.

Please see Table 1 for summary of characteristics of Demoralisation studies meeting eligibility criteria for inclusion in this systematic review.
Studies are tabulated according to the study measure used and oncology/non-oncology populations.

Prevalence of demoralisation syndrome based on mean scores and % prevalence
Pooled average of the mean demoralisation score was 24.3 (95% CI 21.3-27.3) (I^2= 99%) in all studies reporting mean DS score (8802
participants from 30 studies). Subgroup analysis revealed pooled mean score of 25.8 (95% CI 23.2- 28.3) in oncology studies (6863 participants

from 20 studies) and pooled mean score of 21.4 (95% CI 13.9- 28.8) in non-oncology studies (1939 participants from 10 studies) (see Forest
plot 1). Further analysis in advanced cancer populations revealed overall mean of 27.4 (95% CI 24.0- 30.8; I^96%, 1751 participants from 6
studies) (see Forest plot 2).

In all studies reporting % prevalence for clinically significant scores on the DS or DS-II (scores of at least >8 or ‘severe demoralisation’ based on
Robinson (Robinson et al., 2016c) and Mullane’s (Mullane et al., 2009) criteria for clinically significant demoralisation in articles where score
cut offs are not reported), pooled prevalence was 34.7% (range 6-86%; 6350 participants from 27 studies).
In studies examining oncology populations, mean pooled prevalence of participants with scores >8 or ‘severe demoralisation’ on the DS and
DS-II was 35.8% (range 16- 57.6%; 5216 participants from 20 studies). Different studies reported different cut offs for clinically relevant
demoralisation according to the DS; those oncology studies that reported percent prevalence of DS scores >30 (3317 participants from 14
studies) had a mean pooled prevalence of 39.0% (range 16-57.6).

In studies examining non-oncology populations, for studies reporting clinically relevant demoralisation scores (DS-II ≥ 8) or ‘severe
demoralisation’ (7 studies involving 1134 participants), the pooled mean prevalence % was 31.8% (range 6-86).

For the studies using DCPR measure, prevalence of demoralisation was 24.3% (range 15-50%; 1930 participants from 11 studies). Furthermore,
among oncology studies, prevalence was 24.4% (389 participants from 2 studies), while in non-oncology studies it was 24.3% (1541
participants from 9 studies).

Psychometric Analysis
Of the studies included in this review examining psychometric properties of the DS and DS-II, high mean scores were identified in the
‘Emotional distress and inability to cope’ subscale (Bailey et al., 2019; Bovero et al., 2019) which examines emotions associated with being in
control, irritability, distress, isolation, feeling trapped and regret (Robinson et al., 2016b). High mean scores were also observed in the
‘Disheartenment’ (Grassi et al., 2017; Belvederi Murri et al., 2020b), and ‘Sense of Failure’ subscales (Liao et al., 2018) of studies assessing the
DS. The ‘Disheartenment’ subscale assesses participant accordance with feelings of isolation, discouragement, hopelessness and poor coping.
The ‘Sense of Failure’ subscale focuses on identifying self-value, pride in self accomplishment and feeling worthwhile (Kissane et al., 2004)
Overall, the DS was found to demonstrate good psychometric properties in settings outside of cancer (Belvederi Murri et al., 2020b) and when
shortened or transformed into culturally or linguistically adapted scales (Belvederi Murri et al., 2020b; Cheng et al., 2019).

Relationship between demoralisation and DSM syndromes

Multiple studies reported a significant portion of patients who were demoralised yet did not show any symptoms of depression (Grassi et al.,
2017; Bobevski et al., 2015; Cersonsky et al., 2019; Belvederi Murri et al., 2020b), with a higher proportion of ‘low depression and high
demoralisation’ patients compared to ‘high depression and low demoralisation’ presentations (Ignatius and De La Garza, 2019; Tang et al.,
2020). A population was also identified that was found to be demoralised without any evidence of a DSM mood or adjustment disorder as
defined by the Composite International Diagnostic Interview–Oncology (CIDI-O) in accordance with DSM-IV criteria (Vehling et al., 2017). The
distinction between depression and demoralisation has been explored and debated in the literature; the hallmark of demoralisation has been
identified in the prevalence of subjective incompetence and decreased meaning secondary to loss of direction, contributing ultimately to
feelings of helplessness and hopelessness. This contrasts with depression being described as a syndrome of anhedonia with predominant loss
of consummatory pleasure; where there is general loss of motivation rather than a lack of objective to an individual’s goals and purpose in life
(Figueiredo, 2013; Clarke et al., 2003). In the study by Bobevski et al., 2015, a low proportion of respondents with high demoralisation scores
were found to have comorbid moderate to severe depression or anxiety.

Demoralisation was also shown to have significant comorbidity with depression (Arts-de Jong et al., 2017; Bailey et al., 2019; Koo et al., 2018;
Tang et al., 2020; Vehling and Mehnert, 2014; Vehling et al., 2015; Xu et al., 2019), with a high probability of being highly depressed among
highly demoralised patients, and a significant proportion of patients meeting criteria for co-morbid Demoralisation and Depression (Belar et

al., 2019; Bovero et al., 2019; Elfil et al., 2019; Ignatius and De La Garza, 2019; Juliao et al., 2016; Belvederi Murri et al., 2020b; Offidani et al.,
2017; Tecuta et al., 2019). Increasing scores on the HADS-Depression scale were found to correlate with increasing levels of demoralisation
(p<0.001) (Nanni et al., 2018). There was also an elevated probability of being highly demoralised among highly depressed patients (Belar et
al., 2019; Ko et al., 2018; Vehling et al., 2017; Xu et al., 2019) and, in particular, this was noted in the post-operative setting following cardiac
surgery (Liao et al., 2018). Recent network analysis exploring the strength of associations between symptoms has shown how the symptoms of
depression fall into a distinct community quite separate from the symptoms of demoralisation (Belvederi Murri et al., 2020). This network
analysis also described features of somatisation and anhedonia that are present in depression but not demoralisation (Belvederi Murri et al.,
2020a).
A comorbidity between demoralisation and anxiety was also demonstrated (Bobevski et al., 2018; Vehling et al., 2017; Xu et al., 2019). In
examining the relationship between psychiatric disorders and demoralisation, patients with substance dependence experienced higher levels
of demoralisation with comorbid anxiety disorders. Conversely, demoralisation levels were observed to be relatively lower in patients with
psychotic disorders (De Weert et al., 2017).

Sociodemographic factors

Various medical, psychological and sociodemographic associations are evident in these studies of demoralisation. These have been
summarised in Tables 2, 3 and 4 with associated number (N) of studies and participants, in addition to likelihood of association based on
participant size, number of studies sharing common findings and associations that require further exploration.

Physical health burden
Overall, it was found that poor physical health (Arts-de Jong et al., 2017; Koo et al., 2018; Vehling and Mehnert, 2014; Quintero Garzón et al.,
2018; Philipp et al., 2019) and burdensome physical symptoms (Bailey et al., 2019; Offidani et al., 2017; An et al., 2018) are strongly correlated
with demoralisation. Attachment security (Vehling et al., 2019) and dignity (Bovero et al., 2019; Vehling and Mehnert, 2014) were found to
mediate the relationship between demoralisation and physical problems. Additionally, functional impairment (Koo et al., 2018; Bobevski et al.,
2014) and treatment related factors such as treatment stage, advanced disease (Tang et al., 2020; Nanni et al., 2018; Bobevski et al., 2018; Li
et al., 2016) and time since diagnosis (Grassi et al., 2017; Li et al., 2015) were found to influence demoralisation. Demoralisation was also
found to be a significant predictor for physical quality of life in a longitudinal study examining cardiac transplant patients (Wu et al., 2018), and
demoralised patients were found to be less likely to achieve blood pressure control in a study population of patients with hypertension
(Offidani et al., 2017). The physical health factors associated with demoralisation are summarised in Table 2.

Demographic factors
Generally inconsistent associations were identified between demographic and medical factors, as observed in previous systematic reviews.
Some studies identified no demographic factors as being predictive of higher levels of demoralisation, although cohort sizes were smaller for
some (see Table 3) with potential sample bias resulting (Arts-de Jong et al., 2017; Bovero et al., 2019; Cersonsky et al., 2019; Quintero Garzón
et al., 2018). Other studies reported that patients with lower education (Bailey et al., 2019; Bobevski et al., 2015; Ko et al., 2018; Li et al., 2016;
Tang et al., 2020; Wu et al., 2018), lower income level (Cheng et al., 2019; Li et al., 2017; Li et al., 2016; Tang et al., 2020), female gender (De
Weert et al., 2017; Ignatius and De La Garza, 2019; Ko et al., 2018; Li et al., 2016) and younger age (Vehling et al., 2015; De Weert et al., 2017;
Ignatius and De La Garza, 2019; Koo et al., 2018) were relatively more demoralised. Additionally, being single/non-partnered (Ignatius and De
La Garza, 2019; Li et al., 2016) and having poor social support was found to mediate higher demoralisation (An et al., 2018; Philipp et al., 2019;
Quintero Garzón et al., 2018; Li et al., 2017). The demographic factors associated with demoralisation are summarised in Table 3.

Psychological factors

Demoralisation was negatively associated with post traumatic growth (Li et al., 2015; Salimi Kivi et al., 2019), sense making and benefit finding
(Li et al., 2015). Patients who made more sense of their cancer diagnosis, found greater benefit from, or experienced higher post traumatic
growth after diagnosis experienced less demoralisation (Li et al., 2015).
Other factors such as positive life orientation, avoidance and resignation coping methods (Tang et al., 2020; Offidani et al., 2016), attachment
security (Vehling et al., 2019) and death anxiety (An et al., 2018) were also found to be significantly related to demoralisation. There is
evidence of higher levels of perceived relatedness (Philipp et al., 2019), greater subjective incompetence and less resilience in those
demoralised (Cersonsky et al., 2019). The psychological factors associated with demoralisation are summarised in Table 4.

Quality of life
High demoralisation was associated with a significantly lower quality of life (Bobevski et al., 2018; Nanni et al., 2018; Wu et al., 2018; Tang et
al., 2020; Arts-de Jong et al., 2017). Demoralisation was found to affect mental (Tang et al., 2020; Nanni et al., 2018) and physical aspects of
QOL (Nanni et al., 2018; Wu et al., 2018); depression was found to mediate the relationship between demoralisation and physical aspects of
QOL (Tang et al., 2020).

Risk of suicide

Suicidal ideation was significantly associated with demoralisation in five studies reporting on 2413 participants (Bobevski et al., 2018; Elfil et
al., 2019; Fang et al., 2014; Nanni et al., 2018; Xu et al., 2019). Additionally, demoralisation was found to have a greater influence on suicidal
ideation then depression (Fang et al., 2014; Vehling et al., 2017) and other psychiatric disorders such as adjustment disorder (Vehling et al.,
2017). Patients with depression and demoralisation were also identified to have an increased level of suicidal ideation above the effect of
depression alone (Fang et al., 2014).

DISCUSSION
Overall, among 40 studies comprising 9,920 mostly medically ill participants, demoralisation has been prevalent in 24-35% using a validated
self-report measure reporting % prevalence. A higher prevalence (24-36%) was found in oncology compared to non-oncology (24-32%) studies.
This is a higher prevalence than reported in a previous systematic review conducted by Robinson et al., 2014. Study heterogeneity explains the
variance in findings. Overall demoralisation is prevalent across a range of different clinical sample populations and is a ‘trandiagnostic’
construct that signifies the importance of coping across different medical predicaments (Dalgleish et al., 2020).

The importance of recognizing demoralisation

These studies have repeatedly differentiated demoralisation from other mood disorders such as depression, anxiety and adjustment disorder.
There was a significant proportion of patients that were demoralised yet did not show any symptoms of depression, which is consistent with
previous studies in oncology (Mehnert et al., 2011; Kissane et al., 2004; Mullane et al., 2009; Tecuta et al., 2015; Robinson et al., 2015) and
mental illness populations (Grassi et al., 2020). Recent studies using network analysis have confirmed that symptoms of depression occupy a
separate community to the symptoms of demoralisation (Belvederi Murri et al., 2020a).

Comorbidity between demoralisation and depression has been consistent, however, throughout these empirical studies and was well
exemplified in the latent class analysis by Bobevski and colleagues (Bobevski et al., 2018). There was a high probability of the demoralisation
symptoms being found among the cluster with the most severe psychopathology, as well as the cluster reflecting adjustment disorders. When
the symptoms of demoralisation are conceptualized as phenomena associated with poor coping, it is quickly apparent that these are expected
with mental illnesses, such as major depressive episodes and anxiety disorders, as well as in settings of maladaptive adjustment. A recent
study exploring demoralisation in a psychiatric sample of patients with affective, non-psychotic disorders corroborated the high prevalence of
demoralisation (50%) among comorbid anxiety, adjustment or depressive disorders (Grassi et al., 2020).

Significantly, suicidal ideation was strongly associated with demoralisation and demoralisation was identified to mediate suicidal ideation
independently of anhedonia.
This has been emphasized in a more recent study (Costanza et al., 2020a). Additionally hopelessness in relation to demoralisation has both
historically and more recently been found to mediate associations with increased levels of suicidal ideation, in both refugee and cancer
populations (Briggs and Macleod, 2010; Liu et al., 2020). This is consistent with hopelessness being independently associated with a desire for
hastened death in terminally ill cancer patients (Breitbart et al., 2000).

Demoralisation presents commonly in patients with schizophrenia and contributes to a greater risk of suicide independent of depression
(Berardelli et al., 2019). Overall, this suggests a strong clinical need to identify demoralisation because of its elevated suicidal risk and the need
for more urgent institution of management and therapeutic intervention.

Importance of sociodemographic factors associated with demoralisation
Physical health burden was found to be positively correlated with demoralisation. Treatment related factors were also significant; hospitalised
patients, patients currently receiving treatment, a shorter time since diagnosis and more advanced cancer or recurrent disease were
associated with higher levels of demoralisation. Previous studies have demonstrated that psychological and social factors related to physical

illness rather than the severity of the illness contribute to the incidence of demoralisation (Clarke et al., 2005). Palliative treatment intention is
more influential than tumour stage in an oncology population (Vehling et al., 2012).

As reported in prior systematic reviews (Robinson et al., 2015; Tecuta et al., 2015), inconsistent evidence surrounds some demographic factors
such as age. Generally, poorer education, lower income, being female and single or lacking social supports were associated with higher
demoralisation. Lower socioeconomic status is associated with chronic stress that contributes over time to learned helplessness and
powerlessness (Baum et al., 1999); this correlates directly with the core features of hopelessness and loss of purpose inherent to
demoralisation. Additionally, social isolation can potentially magnify the threat of existential distress associated with demoralisation. This is
reflected in previous studies identifying a positive relationship between poor social and family support on higher demoralisation (Marchesi and
Maggini, 2007; Mehnert et al., 2011); the wider literature also corroborates the association between stronger social supports and how this
fosters neurobiological changes that contribute to higher levels of resilience, lower emotional distress and increased ability to cope with illness
(Ozbay et al., 2007; Kim et al., 2010).

Exploring the need to understand demoralisation as it transcends culture and language

A high prevalence of demoralisation has been observed across cultures. The meaning of life may differ as do Western and Eastern world views.
Cultural stigma and perception surrounding suicidal ideation can vary across ethnicities (Xu et al., 2019). Irrespective of this though, the
enduring human need for dignity and meaning in life appears to transcend cultures. Significant psychological factors identified here such as
sense-making, perceived relatedness and subjective incompetence would do well to be explored in a cultural framework; this will assist the
interpretation of demoralisation through various ethnic and cultural nuances. De Figueiredo and Gostoli have alluded to the importance of
understanding ‘idioms’ of distress unique to specific cultures (de Figueiredo and Gostoli, 2013).

Compared to previous reviews (Tecuta et al., 2015; Robinson et al., 2015; Tang et al., 2015) this review provides further evidence of the high
prevalence of demoralisation across a range of medical illnesses; in addition to its differentiation from and comorbidity with related constructs
such as depression and anxiety, the associated risk of suicide and related sociodemographic and psychological factors. This contributes further
to the evidence corroborating the significance and diagnostic value of demoralisation syndrome since these previous reviews were completed
in 2015.

Clinical significance

Given the past two decades of research exploring demoralisation, its clinical significance and distinction from other syndromes, consideration
of its inclusion within DSM and ICD systems continues to be warranted. The incorporation of the mental state of demoralisation as a “specifier”
within the DSM nosological system appears to be worthwhile. Specifically, demoralisation can be diagnosed when there is the presence of the
core symptoms of ‘hopelessness’, ‘low morale’, ‘poor coping’ and ‘meaninglessness’. There is immediate applicability of this specifier to the
diagnoses of mood and adjustment disorders, with particular value in bringing attention to poor coping in depression and increasing targeted
therapy towards sustaining purpose and meaning in life. Indeed, a vignette-based study of the utility of this specifier revealed enhanced illness
understanding, treatment selection and ease of communication with colleagues (Kissane et al., 2017). The growing body of research identifying
demoralisation as a mediator of suicidal ideation serves as a powerful reason to proceed with this development.

Recent studies have generated evidence for the unidimensional nature of adjustment disorder, with proposals for ICD-11 suggesting that
adjustment disorder be elevated from a hierarchical classification system to the status of an axis one disorder (Glaesmer et al., 2015). Other
critiques have expressed concern about the subjective interpretation of maladaptive coping to generate a diagnosis of adjustment disorder
(Strain, 2019). When the phenomenology of low morale and poor coping associated with the development of demoralisation are brought to
the fore, as in this review, a richer set of symptoms becomes possible to strengthen the diagnostic criteria for adjustment disorder and allow it

to be identified more readily in clinical populations. Historically, there has been a paucity of empirical studies on adjustment disorder (Bachem
et al., 2017). There is much still to do and with relative urgency!

Limitations
Limitations of this review include the heterogeneity of the study populations, inconsistent thresholds for clinical significance across these
studies, and variation in outcome measures. Additionally, the use of convenience sampling and/or a cross sectional design create a selection
bias that hinders generalizability. We examined studies published in the English language. However, there were a variety of countries
represented, including but not limited to Canada, The Netherlands, Spain, Germany, Italy, Australia, China, Taiwan and the United States. Also,
despite the inclusion criteria extending to medical illnesses beyond cancer, the majority of the studies (59%) still represented the experiences
of oncology patients. This is a consequence of the early research alignment of demoralisation studies.

Future directions
Demoralisation is currently being examined in patients with epilepsy (Terza et al., 2019), type 2 diabetes (Benasi et al., 2019), refugees (Briggs
and Macleod, 2010) and veterans (Kelsall et al., 2016). Further studies are needed in prison populations where there is already existing

evidence of existential distress and loss of life meaning (Vanhooren et al., 2015), in addition to psychiatric disease, adolescents and young
adults and elderly populations.

This review further cements the need for recognition of demoralisation in various patient settings with the view to initiate targeted
intervention and prevent significant morbidity. In addition to cognitively-oriented and existential therapies, meaning-centered therapy has
been identified as a targeted treatment for demoralisation (Kissane, 2017). The semi structured intervention, ‘Managing Cancer and Living
Meaningfully’ (Nissim et al., 2012) has shown a moderate effect size in ameliorating demoralisation in patients with high baseline death
anxiety (Caruso et al., 2020; Rodin et al., 2018). Additionally logotherapy, a therapy developed based on individuating life and existential
meaning, has been demonstrated to be effective in the reduction of demoralisation in breast and gynaecological cancer patients (Sun et al.,
2021).

In our global world, the role that the Covid-19 pandemic has played in generating demoralisation is worth further exploration. As Covid-19
presents an existential threat which can evoke helplessness, its important risk of inducing suicide in the context of loss of the meaning of life
becomes clear (Costanza et al., 2020b).
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TABLE 1: Characteristics of Demoralization Studies meeting eligibility criteria for systematic review (2014-2020) and using the Demoralization Scale (DS), Demoralization Scale-II (DS-II)
or Diagnostic Criteria for Psychosomatic Research (DCPR)
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gender matched, 50%

family support, poorer education & low

matched participants (from

(n=182) of participants had

monthly income

overall sample of 411 cancer

DS MV scores >30.

0.95

patients)
13

Li et al., 2016;

Cross sectional descriptive

Explore correlations

Taiwan (Same data

study of 411 participants-

between

used as above but

cancer patients

demoralization,

different

medical & socio-

focus/analyses

demographics

performed)

DS-MV

Mean DS-MV score 30.08
(SD 13.68)

0.95

14

Quintero Garzon et

Cross sectional design based

Examine association

DS- German

Mean DS score 32.0 (SD

al., 2018; Germany

on single, blinded, randomized

between patient’s

Version, BDI-II-

15.2).

controlled trial intervention

perceived relationship to

German Version,

Prevalence: 37% (DS > 36),

study of advanced cancer

healthcare providers and

MSAS, QUAL- EC-P

53.4% (DS >30)

patients, 187 patients with

demoralization



No associations between age, sex or

0.95

relationship status and demoralization


Less favourable relationship with HCP
associated with higher demoralization

stage III or IV cancer
15

Tang et al., 2020;

Cross sectional study, 296

Explore factors influencing

DS-MV, PHQ-9, SF-

Mean DS score 30.4 (SD 13)

China

patients with cancer (various

depression, demoralization,

12V2, CLOT-R,

Prevalence: 47% (DS >30)

types)

quality of life

BHS



28% experienced low level of

0.95

depression but high level of
demoralization.


Demoralization was correlated with
depression (r=0.653, P<0.001),
hopelessness (r=0.661, P<0.001),
positive life orientation (r=-0.471,
P<0.001), avoidance and resignation
(r=0.498, P=0.004; r=0.586, P<0.001),
quality of life (r=-0.227 to -0.519, all
P<0.001).



Demoralization associated with younger
age, poorer education, lower income, &
advanced cancer

16



Vehling et al.,

Mixed cross-sectional study of

Examine association

DS, DT, PDI, PHQ-

Mean DS score 19.1 (SD

2014; Germany

112 inpatients, mixed tumour

between physical

9, ISSS-8

11.7)

loss of dignity, number of physical

sites at early and advanced

symptoms, loss of dignity &

Prevalence: 9% (DS > 36);

problems & demoralization

disease stages

demoralization

11% (DS 30-35)

Significant associations found between

0.95



Mediation hypothesis supports
conceptual assumption that higher
number of physical symptoms may
heighten risk for loss of a sense of
dignity and lead to higher demoralization

17

Vehling et al.,

Cross sectional study of 55

Frequency of

DS, PHQ-9-

Mean DS score 24.6 (SD

2015; Germany

terminally ill cancer patients

demoralization, association

German Version,

14.5).

with individual and disease

GAD-7, KPS

Prevalence: 19% (DS > 36);

related characteristics,



Mean levels highest on the

0.9

disheartenment subscale


10% (DS 30-35)

Positive association between
demoralization and anxiety, and

analyse the association

between demoralization and depression

between demoralization and
preference to discuss
expected survival
18

DS, PHQ-9, CIDI-O

Mean DS score 20.6 (SD



Vehling et al.,

Cross sectional study, 430

Examine relationships

2017; Toronto

mixed cancer patients, early

between demoralization,

13.6)

mood/anxiety disorder in 7.1% and with

stage disease

mood, anxiety, & adjustment

Prevalence: 21% (DS >30)

an adjustment disorder in 2.4%; 13.5%

Demoralization co-occurred with a

disorders, as assessed with

of the patients were demoralized in

a standardized diagnostic

absence of any mood or anxiety

interview;; assess relative

disorder; 11.1% were demoralized in

risk (RR) for mental

absence of any mood, anxiety, or

disorders associated with

adjustment disorder, 17.2% were

demoralization; and the

demoralized but did not fulfill the criteria

relative contribution of

for a mood disorder

demoralization to suicidal

1.0



ideation beyond the impact
of mental disorders.

Demoralization was associated with a
significantly increased risk for a mood
disorder (RR, 7.8; 95% CI, 3.4-17.9), an
anxiety disorder (RR, 3.7; 95% CI, 2.26.1), and suicidal ideation (RR, 3.5; 95%
CI, 1.9-6.2).



Among those without a mood or anxiety
disorder, demoralization was also
associated with a significantly increased
risk for suicidal ideation (RR, 2.8; 95%
CI, 1.2-6.7)



Demoralization had a significant
contribution to suicidal ideation beyond
the impact of mental disorders (RR, 2.0;
95% CI, 1.1-3.5).

19



Vehling et al.,

Cross sectional sample of 382

Examine contribution of

DS; PHQ-9, ECR-

Mean DS score 25.9 (SD

2019; Toronto

patients with advanced cancer

attachment security to

16, MSAS-SF

14.2), Prevalence: 35% (DS

attachment security & demoralization,

recruited from outpatient

demoralization; test

> 30); depression in 26%;

greater than that with depression;

oncology clinics

hypothesis that attachment

19% were demoralized but

security is associated with

not depressed; and 16%

moderator of association between

less vulnerability to

were demoralized &

physical symptoms and demoralization;

demoralization

depressed.





Moderate negative association between

Attachment security is a significant

Significant associations of attachment
anxiety and attachment avoidance with
demoralization.

1.0

20



Xu et al., 2019;

Cross sectional study, 303

Investigate prevalence of

DS-MV, PHQ-9,

Mean DS-MV score 30.10

China

patients with cancer

demoralization among

GAD-7, MINI

(SD 14.44)

to treatment satisfaction, education level

cancer patients in mainland

Prevalence: 49.5% (DS >

& place of residence. Demoralization

China and its contribution to

30).

was associated with depression, anxiety

suicidal ideation

Differences in demoralization according

0.95

and suicidal ideation


After controlling for treatment
satisfaction, demoralization and
depression were identified as
independent risk factors for suicidal
ideation. Specifically, patients with high
demoralization were at 5.85-fold greater
risk of suicidal ideation

21

Philipp et al., 2019,

Longitudinal study of 307

Level of perceived

DS, PTGI- modified

Mean DS score 23.8 (SD

Germany

oncological inpatients over 1

relatedness and impact on

version, MSAS,

13.5) at baseline

year

demoralization/death

LAP-R

Prevalence 31.2% (DS > 30)



No significant differences in

1.0

demoralization over time after 1 year


acceptance

Higher level of perceived relatedness
predicated lower demoralization at T3;



More physical symptoms predicted
higher demoralization, stronger
perceived relatedness predicted less
demoralization

Studies of Non-oncology medical study populations using the DS or DS-II
Author, Country

Study design, sample
characteristics and size

Study Objectives

Study measures

Demoralization prevalence
results

Other key findings

Quality
score

1



Bailey et al., 2019;

Cross sectional study of 73

Examine demoralization in

DS-II; PHQ-9;

Mean DS-II score 7.8 (SD

Australia

patients with chronic illness in

rural chronically ill

MSAS, CCI

26.4).

the distress and coping subscale. High

rural setting

population

Prevalence: 27.4% (DS-II

DS score associated with poorer

≥11).

education (p=0.01);


Demoralized group scored higher on

0.85

Demoralization associated with
symptom burden (p <0.001) &
depression (p <0.001)

2



Bobevski et al.,

Cross sectional study of 209

Examine psychometric

DS, BaM-13,

Mean DS score 30.9 (SD 15.5)

2014; Australia

women in postnatal period

properties of Demoralization

DASS-21, EPDS

6% scored DS score >30

improvement in demoralization (57.5 %)

admitted to private hospital

scale in hospitalized women

Post-treatment mean DS

than in depression (34.8 %) and anxiety

mother-baby unit

in postnatal period receiving

score 18.4 (SD 12.4)

(9.8%) symptoms

Same as Bobevski
et al., 2018,

treatment for postnatal

postnatal version:

depression



More participants showed a significant

1.0

High demoralization associated with
negative experiences of motherhood

same population

(r=0.79) and functional impairment,

used (nil

independent of depression and anxiety

demoralization data

symptoms


reported in this
article)

50% of participants rated DS between
7/10-10/10 on perceived relevance to
present situation- women with higher
demoralization scores perceived scale
as more relevant.

3



Loss of meaning doesn’t appear to be a

Bobevski et al.,

Cross sectional telephone

Examine psychometric

DS-postnatal

Mean DS score 14.9 (SD 12,

2015; Australia

survey of primiparous women

properties of DS in

version, PHQ-9,

range 0-67), median 12.0;

salient experience in early post-natal

attending community maternal

community mothers,

GAD-7,

Prevalence: 8% (DS >30)

period

1.0



health centres (n=400) who

prevalence of demoralization

Personality

had recently given birth in prior

among primiparous women,

Vulnerability

DS: depressed (32%) or anxious

4 weeks and receiving post-

and factors associated with

Subscale of

(38.7%)

partum care from participating

demoralization in early

VPSQ, BPD, IBM

Maternal and Child Health

postnatal period;



Proportions of respondents with high

Association between demoralization
and women’s early postnatal

nurses

experiences (relationship with partner)
+ negative experiences of motherhood


Demoralization associated with nonEnglish speaking back- ground, lower
education, past psychiatric history

4



Cersonsky et al.,

Prospective longitudinal study

Determine prevalence of

DS-II, SIS, BRS,

Prevalence of demoralization

2019, USA

of 60 patients with essential

demoralization in ET, assess

TDQ, CIRS,

was 13.3% (DS-II >8) (95% CI

10%; 54% depressed, not demoralized;

tremor

subjective

MMSE, MoCA,

6.9–24.2%)

25% demoralized, not depressed.

incompetence/resilience;

GDS, CDR, IADL,

Mean DS-II score 3.6 (SD 4.4)

assess clinical correlates

GAD-7



Comorbid demoralization & depression

1.0

Demoralization associated with
subjective incompetence (SIS), less
resilience (BRS), greater depression
and anxiety but not tremor severity.

5

DS

Mean DS score in clinical



De Weert-Van

Longitudinal study of 217

Assess level of

Oene et al., 2017;

patients with co-occurring

demoralization in various

cohort 17.28 (SD 11.8), in

experienced highest levels of

The Netherlands

substance use disorders and

subcategories of patients

community cohort 17.44 (SD

demoralization in comorbidity with

other psychiatric disorders and

with co-occurring disorders

11.7) at baseline.

anxiety disorders, and the lowest in the

179 community-based

with substance dependence,

Prevalence: 86% (DS> 26)

presence of psychotic disorders

individuals

assess level of

Substance dependence patients

0.95



remoralization after 1 month
of inpatient treatment

Clinical cohort had demoralization
scores that were higher on all
subscales



Correlation between gender, age and
demoralization

6

Kivi et al., 2019;

Cross sectional study of 146

Investigate demoralization

Iran

patients with multiple sclerosis

among patients with multiple

DS, PTGI

Mean DS score 34.71 (SD



18.22)

0.95

demoralization and posttraumatic

sclerosis
7

Inverse relationship between

growth (p<0.001; r= -.057)


Liao et al., 2018;

Prospective correlational study,

Investigate prevalence of

DS- Mandarin

Prevalence pre-surgery:

Taiwan

convenience sampling to recruit

and contributors among

Version, PHQ-9,

44.7%; Prevalence post-

employment status (retired) predicted

76 participants undergoing

patients before and after

Perception of ICU

surgery: 36.8% (According to

demoralization before surgery; post-

cardiac surgery

cardiac surgery

Stay

Mullane et al. (2009) criteria

operative depression predicted after

Questionnaire

for cut off (1))

surgery

Preoperative depression scores and

0.9

Mean DS score preop 17.36
(SD 12.04), mean DS score
post op 12.8 (SD 10.26)
8



Wu et al., 2018;

Longitudinal study using

Compare cardiac transplant

DS; MOS SF-12;

Mean intercept coefficient

Taiwan

convenience sampling of 99

recipients for quality of life,

HPLP-II

39.14 (SE 11.98)

education, religion, quality of life,

cardiac transplant recipients

demoralization and health-

37% of population with DS

mechanical circulatory support and

related lifestyle; identify the

score >30 at baseline

medical variables.

Demoralization was associated with

0.9

predictors of quality of life.
Studies of Oncology study populations using both DCPR and DS scale
Author, Country

Study design, sample
characteristics and size

Study Objectives

Study measures

Demoralization prevalence
results

Other key findings

Quality
score

1

Grassi et al., 2017;

Cross sectional study of 194

Explore validity and

DS- IT, DCPR/D,

Mean DS-IT score 23.55 (SD

Italian cancer patients

application of Italian version

KPS, PHQ-9, Mini-

14.01)

of the DS in cancer

MAC/HH



Sixteen patients who were severely

0.95

demoralized were non-cases on the
PHQ-9 (16/43, 48.5%), while among

ambulatory settings,

Prevalence of high

those who were moderately severe

examine factor structure,

demoralization: 24.2%

demoralized or moderately

concurrent and divergent

(according to Mullane et al.

demoralized, 11 (11/17, 78.5%) and 85

validity of the DS-IT

(2009)), 17% (according to

(85/104, 82%) respectively, did not

Robinson et al. (2016))

show any symptom of depression, (χ2,
28.8, df 3, p=0.0001)

DCPR diagnosis of
demoralization: 23.7%.
2

Nanni et al., 2018;

Observational, cross sectional

Prevalence of

DCPR/D, DS,

25.1% clinical demoralization

Italy

study assessing 195 cancer

demoralization in Southern

HADS, PHQ-9

found on the DCPR/D

outpatients

Europe and relationship with

interview (49 patients)



DCPR/D cases showed higher scores
on all the DS subscales (p<0.001)



quality of life and

DCPR/D+ or DS-demoralized patients
showed higher scores on HADS-

psychological variables

Mean DS score 24.74 (SD

Anxiety, HADS-Depression, HADS-

among cancer patients

13.38)

Total, and PHQ-9, with increasing

Prevalence of high

scores according to increasing levels of

demoralization on the DS:

demoralization (all p<0.001)

22% (based on Robinson et al.



(2016)) and 18% (based on
Mullane et al. (2009))

Demoralization is associated with
poorer quality of life



Patients with metastatic disease had
higher scores on the total DS and DSDisheartenment subscale

0.95



8.3% had suicidal thoughts, one quarter
were not depressed on the PHQ-9 but
were demoralized

Studies of non-oncology medical populations using both DCPR and DS scale
Author, Country

Study design, sample

Objective

Study measures

characteristics and size
1

Elfil et al., 2019; US

Demoralization prevalence

Other findings/results:

results

Quality
score



Case control study, 186

Examine suicide risk and

DS, DCPR-D,

Demoralization (n, %) for

patients with Parkinson’s

lifetime suicidal ideation in

SBQ-R, BLDS, C-

DCPR-D; 37/186 (19.9) vs

lifetime depression history, insomnia

disease and 177 age matched

Parkinson disease (PD)

SSRS, ISI, SBQ-

control- 19/177 (10.7)

and demoralization

controls

patients versus controls and

17, nM-EDL from

p = 0.02

how depression,

MDS-UPDRS,

demoralization, and

QUIP-RS



PD participants more likely to have

1.0

Demoralization associated with higher
SBQ-R (suicidal rating measure) in

Mean DS score 15.8 (SD

insomnia are associated

15.2), higher then control

with suicidality.

population mean DS score

linear regression analysis


Demoralization significant predictor of
high suicide risk but not depression

11.5 (SD 12.7)
2

Koo et al., 2018; US



Cross sectional prospective

Determine prevalence and

DS, DCPR-D,

Prevalence: 18.1% (17/94) in

study of 94 patients with

associated features of

UPDRS-m, PHQ-9

PD compared to 8.1% (7/86)

discordance in the PD than the control

Parkinson’s disease matched

demoralization in

in matched controls (p = 0.05).

group

with 86 community controls

Parkinson’s disease



Greater depression-demoralization

More comorbid depressed-demoralized
individuals in the PD than control group
(12.8% vs 3.5%, p = 0.01).



Demoralized compared to nondemoralized participants with PD had
significantly higher UPDRS-m scores,

1.0

higher mean PHQ-9 scores and higher
mean PD scores.


In participants with PD, demoralization
but not depression was associated with
motor dysfunction, suggesting that
demoralization more than depression is
tied to functionality.

3



Murri et al., 2019;

473 participants recruited from

Investigate psychometric

DCPR/D, DS,

DCPR/D prevalence: 40%

Italy

medical wards, convenience

properties of DS-Italian

PHQ-9, BSI-18,

Mean DS-IT score 31.57 (SD

cases of depression, 27 (14.8%) were

sample

among medically ill

EQ-5D

19.37)

not demoralized, whereas of those

Among 182 patients who were PHQ-9

inpatients and develop

PHQ-9 non-depressed (n=265) 53

shorter screening version,

(20.0%) were demoralized, with an

examine relationship of DS-

overlap between depression and

24 and shorter version with

demoralization of 34.7% (n=155).


psychological and QOL
variables

0.95

DS-IT 24 item displayed good
psychometric properties



DS-6 brief version showed comparable
Area Under Curve, sensitivity and
specificity to the DS-24 against the
DCPR goal standard.

Studies of non-oncology study populations utilising the DCPR only
Author, Country

Study design, sample
characteristics and size

Study Objectives

Study measures

Demoralization prevalence
results

Other key findings

Quality
score

1



Offidani et al., 2016;

Observational, cross sectional

To examine psychological

DCPR/D,

Prevalence: 25.7%

US

study assessing 70 patients

distress and well-being in

Psoriasis and

demoralization

persistence, harm avoidance and self-

with psoriasis

patients with mild, moderate

severity index

Patients with greater severity

directness

& severe psoriasis

(PASI)

(PASI >19) presented with



higher demoralization
2

Demoralization associated with higher

0.85

Moderate to severe psoriasis more
likely to report demoralization



Offidani et al., 2017;

TRIUMPH study- randomised

TRIUMPH (Trial Using

DCPR-D, PASI,

Prevalence: 15% of patients

US

control trial, 175 out of 238

Motivational Interview,

SCID-I, SQ PWB,

were demoralized (n=27)

participants enrolled in trial of

Positive Affect, and Self-

TCI

African American patients with

affirmation in African

hypertension

Americans with

achieving blood pressure control were

Hypertension)

6.5x greater than for a demoralized

Demoralized patients are less likely to

1.0

achieve blood pressure control than
participants without affective conditions


Without psychological distress, odds of

patient
3

Rafanelli et al.,

Cross-sectional prospective

Evaluate clinical/subclinical

DCPR-D, SCID-I,

2016; Italy

study of 68 chronic heart

psychological distress and

SQ, PWB

failure patients

well-being in CHF

Prevalence: 20.6%

0.85

outpatients
4



Tecuta et al., 2019;

Cross sectional study of 79

Examine demoralization,

DCPR- D, SCID-I,

Prevalence: 20.3%

Italy

patients with eating disorders

subclinical distress, and

CID, BDI-II, PWB,

12 with helpless

greater distress, lower psychological

psychological well-being.

EAT-40

demoralization, and 4 with

wellbeing and higher BDI-II scores.

hopeless demoralization.



Demoralization was associated with

Demoralization was associated with
worse functioning in environmental
mastery, positive relations with others,
purpose in life, and self-acceptance

0.9

5



Tesio et al., 2019;

Cross sectional study of 98

Investigate prevalence of

DCPR, HADS-

Prevalence of demoralization

Italy

women with fibromyalgia and

psychosomatic syndromes

Depression and

(50% vs 18.4%) in FM patients

and depression and anxiety symptoms,

98 women with Rheumatoid

in fibromyalgia patients vs

Anxiety subscales,

compared to RA patients,

demoralization was statistically

Arthritis

rheumatoid arthritis patients

SF-36, VAS

(P<0.0001)

significant

Even after controlling for pain intensity

Legend:
BaM-13 (Being a Mother Scale); BDI- II (Beck Depression Inventory II); BHS: Beck Hopelessness Scale; BLDS (Brief Lifetime Depression Scale); BPD (Barr Parental Diary); BRS (Brief Resilience
Scale); BSI: (Brief Symptom Inventory-18),BSI/BSS: Beck Scale for Suicidal Ideation; CCI (Charlson Comorbidity Index); CDR (Clinical Dementia Rating); CID (Clinical Interview for Depression);
CIDI-O (Composite International Diagnostic Interview- Oncology); CIRS (Cumulative Illness Rating Scale); CLOT-R: Revised Life Orientation Test; C-SSRS (Columbia-Suicide Severity Rating
Scale; CWS (Cancer Worry Scale); DADDS (Death and Dying Distress Scale); DASS-21 (Depression Anxiety Stress Scale); DS: Demoralisation Scale; DT (NCCN Distress Thermometer); EAT-40
(Eating Attitudes Test-40); ECR-16 (Experiences in Close Relationships Scale); ECR-M16: modified Experiences in Close Relationships scale; EPDS (Edinburgh Postnatal Depression Scale);
EORTC QLQ-C30 (Quality of Life Questionnaire-Core 30); ESAS-r (Edmonton Symptom Assessment System- revised); EQ-5D-3L (EuroQol-5D); FACIT-Sp-12: Functional Assessment of Chronic
Illness Therapy – Spiritual Well-Being; GAD-7 (Generalized Anxiety Disorder-7 questionnaire; GDS (Geriatric Depression Scale), HADS (Hospital Anxiety and Depression Scale); HPLP-II (Health
Promoting Lifestyle Profile- II); IADL (Lawton Instrumental Activities of Daily Living Scale); IBM (Intimate Bonds Measure); ISI (Insomnia Severity Index); ISSS-8 (Illness-Specific Social Support
Scale Short Version-8); KPS: Karnofsky Performance Status; LAP-R (Life Attitude Profile-Revised); Mini-MAC/HH (Mini-Mental Adjustment to Cancer Hopelessness- Helplessness (HH) subscale;
MMSE (Mini-Mental State Examination); MoCA (Montreal Cognitive Assessment); MOS SF-12 (Medical Outcome Study Short Form); MQOL (McGill Quality of Life Questionnaire); MINI (Mini
International Neuropsychiatric Interview); MSAS: Memorial Symptom Assessment Scale; MSAS-SF (Memorial Symptom Assessment Scale- Short Form); nM-EDL (Non-Motor Aspects of
Experiences of Daily Living) from MDS-UPDRS (Movement Disorders Society- Unified Parkinson’s Disease Rating Scale); PASI (Psoriasis Area and Severity Index); PDI- IT: Patient Dignity
Inventory- Italian Version; PHQ-9 (Patient Health Questionnaire-9); PPS (Palliative Performance Scale); PTGI (Posttraumatic Growth Inventory); PWB (Ryff’s Psychological Well-Being scales);
QUAL-EC (Life Completion subscale of the Quality of Life at the End-of-Life – Cancer questionnaire); QUAL- EC-P (German Quality of Life at the End of Life-Cancer-Psychosocial questionnaire);
QUIP-RS (Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease- Rating Scale); SBQ-R (Suicidal Behaviour Questionnaire-revised); SBQ-17 (Suicidal Behaviour Questionnaire17); SF-8 (Short Form Health Survey); SF-12V2: 12-items Short Form Health Survey; SF-36 (36 Item Short Form Health Survey); SIS (Subjective Incompetence Scale); SQ (Kellner’s Symptom
Questionnaire); STAI (Spielberger State-Trait Anxiety Inventory); TCI (Temperament and Character Inventory); TDQ (Tremor Disability Questionnaire); UPDRS-m (Unified Parkinson’s Disease
Rating Scale- part III); VAS- Visual Analog Scale for Pain; VPSQ (Vulnerable Personality Style Questionnaire SCID-I (Structured Clinical Interview for DSM-IV).

0.75
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TABLE 2: Physical health factors associated with demoralization

Physical health factors

Number of

Total number

positively related to

studies

of participants

association being

demoralization

reporting

in these

meaningful

this

studies

5

988

Physical symptoms

Study references

Likelihood of

Koo et al., 2018;

Strong: >3 studies

associated with disease or

Philipp, Mehnert, Muller,

& clinical common

illness

Reck, & Vehling, 2019;

sense

Quintero Garzón et al., 2018;
Sigrun Vehling & Mehnert,
2014;
Arts-de Jong et al., 2017
Symptom burden or

3

618

severity

An, Lo, Hales, Zimmermann,

Strong: 3 studies &

& Rodin, 2018;

likely association

Bailey et al., 2019;
E. Offidani, Del Basso,
Prignago, & Tomba, 2016
Dignity mediating the

2

347

Bovero et al., 2019;

relationship between

Sigrun Vehling & Mehnert,

demoralization and

2014

Needs further study

physical problems
Attachment security

1

382

S. Vehling et al., 2019

Needs further study

2

303

Bobevski, Rowe, Clarke,

Needs further study

McKenzie, & Fisher, 2014;

yet clinical common

Koo et al., 2018

sense

mediating the relationship
between demoralization
and physical symptoms
Functional impairment

51

Hospitalised patients or

2

611

patients currently receiving

Fang et al., 2014;

Needs further study

Y. C. Li, Ho, & Wang, 2016

yet likely

Grassi et al., 2017;

Needs further study

treatment
Shorter time since

2

394

diagnosis

Y. C. Li et al., 2015

Metastatic disease,

4

Bobevski et al., 2018;

Strong: >3 studies,

advanced or recurrent

Nanni et al., 2018;

high participant

cancer

L. Tang et al., 2020;

numbers; common

Y. C. Li et al., 2016.

sense.

Fang et al., 2014;

Strong: >3 studies,

prognosis such as lung,

Y. C. Li et al., 2015;

common sense

gynaecological,

Ko et al., 2018;

gastrointestinal, head and

Y. C. Li et al., 2016.

Cancers with poorer

4

2,431

924

neck and liver cancers

TABLE 3: Sociodemographic factors associated with demoralization

Demographic factors

Number of

Total number

found to be positively

studies

of participants

association being

related to

reporting

in these

meaningful

demoralization

this

studies

No demographic factors

4

770

found to be related

Study references

Likelihood of

Arts-de Jong et al., 2017;

Small cohort size

Bovero et al., 2019;

may bias finding

Cersonsky et al., 2019;
Quintero Garzón et al.,
2018 .
Lower education level

6

1,392

Bailey et al., 2019;

Strong: >3 studies,

Bobevski et al., 2015;

high numbers of

Ko et al., 2018;

participants

52

Y. C. Li et al., 2016;
L. Tang et al., 2020;
Wu et al., 2018.
Lower income level

4

1,274

Cheng et al., 2019;

Strong: > 3 studies;

Y.-C. Li, Ho, & Wang, 2017;

may be culturally

Y. C. Li et al., 2016;

influenced

L. Tang et al., 2020.
Younger patients

4

1,288

S. Vehling et al., 2015;

Strong: > 3 studies

De Weert et al., 2017;
Ignatius & De La Garza,
2019;
Koo et al., 2018.
Older and middle-aged

2

707

patients

Female patients

Y. C. Li et al., 2016;

Needs further studies

L. Tang et al., 2020.

4

1,663

De Weert et al., 2017;

Strong: > 3 studies,

Ignatius & De La Garza,

high number of

2019;

participants

Ko et al., 2018;
Y. C. Li et al., 2016.
Single or non-partnered

2

1,333

patients

Ignatius & De La Garza,

Likely association

2019;
Y. C. Li et al., 2016.

Low social support and

4

1,165

Philipp et al., 2019;

Strong: >3 studies,

family/health care

An et al., 2018;

high number of

support as protective

Y.-C. Li et al., 2017;

participants

factor

Quintero Garzón et al.,
2018.

53

TABLE 4: Psychological factors associated with demoralization

Psychological factors

Number of

Total number

found to be positively

studies

of participants

association being

related to

reporting

in these

meaningful

demoralization

this

studies

Death anxiety and desire

2

387

for death
Lower attachment

Study references

Likelihood of

An et al., 2018;

Needs further study

Juliao et al., 2016.

yet common sense

1

382

S. Vehling et al., 2019

Needs further study

2

534

L. Tang et al., 2020;

Likely association

security
Harm avoidance and
resignation coping

E. Offidani et al., 2016.

methods
Greater subjective

1

60

Cersonsky et al., 2019.

Needs further study

5

2407

Bobevski et al., 2018

Strong: >3 studies,

Nanni et al., 2018

high number of

Wu et al., 2018

participants

incompetence and
decreased resilience
Lower quality of life

Tang et al., 2020
Arts- de Jong et al., 2017
Increased suicidal

5

2413

ideation

Bobevski et al., 2018

Strong: >3 studies,

Elfil et al., 2019

high number of

Fang et al., 2014

participants

Nanni et al., 2018
Xu et al., 2019
Psychological factors

Number of

Total number

Study references

Likelihood of

found to be protective

studies

of participants

association being

for demoralization

reporting

in these

meaningful

this

studies

54

Post traumatic growth

2

346

Y. C. Li et al., 2015 (200)

Needs further study

Kivi et al., 2019 (146)
Greater sense making

1

200

Y. C. Li et al., 2015 (200)

Needs further study

1

307

Philipp et al., 2019 (307)

Needs further study

and benefit finding
Higher perceived
relatedness

55

